EVUSHELD COVID-19 monoclonal antibody update

  NewsEditor      Pharmacy

As of Thursday, Jan. 26, 2023, the Federal Drug Administration (FDA) has withdrawn Emergency Use Authorization (EUA) for tixagevimab/cilgavimab (EVUSHELD®) secondary to reduced susceptibility to currently circulating COVID-19 variants. Health and Human Services has suspended allocation and distribution of tixagevimab/cilgavimab (EVUSHELD®). Read the full SBAR here and distribute to your teams as appropriate.

For more information, please read the FDA update here.